Light Therapy Tested for Movement and Thinking Changes in Parkinson's Disease
Tests whole-body light therapy in adults with Parkinson's disease over about 10 weeks.
Plain-language title generated from the registry record
Registry title: Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease
Key facts
- Where
- Yangsan, South KoreaSee the site
Where in South Korea
- Pusan National University Yangsan HospitalYangsan, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pusan National University Yangsan Hospital
- Trial code
- NCT07271927
- Record updated
- 9 December 2025
- Original description
This study aims to exploratorily evaluate the extent of motor and cognitive changes, as well as the safety, resulting from approximately 10 weeks of whole-body photobiomodulation (PBM) therapy (about three sessions per week, once daily, 20 minutes per session) in patients with Parkinson's disease.Read full original descriptionShow less
Evaluation Study of the Effects and Safety of Whole-Body Photobiomodulation Therapy on Motor and Cognitive Changes in Patients With Parkinson's Disease
This study aims to exploratorily evaluate the extent of motor and cognitive changes, as well as the safety, resulting from approximately 10 weeks of whole-body photobiomodulation (PBM) therapy (about three sessions per week, once daily, 20 minutes per session) in patients with Parkinson's disease.
Inclusion: Individuals diagnosed with Parkinson's disease at Hoehn and Yahr stages 1-3 based on medical history and examination; Adults aged 40 years or older; Individuals able to walk independently.
Exclusion: Individuals treated for alcohol dependence within 6 months prior to screening; Individuals with severe cognitive impairment (Korean Mini-Mental State Examination [K-MMSE] score ≤ 9) making it difficult to understand and perform tasks; Patients with dementia other than Parkinson's disease dementia; Individuals with severe neuropsychiatric disorders; Individuals with a history of suicide attempts; Individuals with a history of seizures; Individuals with visual impairment preventing them from reading ordinary text even with corrective lenses; Individuals with hearing impairment preventing them from understanding conversation even with a hearing aid; Individuals with implanted medical or other electronic devices; Individuals experiencing dyspnea while sitting at rest; Individuals who have participated in two or more clinical trials in the same year or in another clinical trial within the past 6 months; Women and men of childbearing potential who are planning pregnancy during the trial or who do not agree to use appropriate contraceptive methods; Pregnant or breastfeeding women; Individuals deemed medically inappropriate for participation by the principal investigator or study staff based on clinically significant findings not otherwise specified above.